-
1
-
-
0030757461
-
Cancer incidence and mortality in the European Union: Cancer registry data and estimates of national incidence for 1990
-
Black RJ, Bray F, Ferlay J, Parkin DM. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1997;33:1075-107.
-
(1997)
Eur J Cancer
, vol.33
, pp. 1075-1107
-
-
Black, R.J.1
Bray, F.2
Ferlay, J.3
Parkin, D.M.4
-
2
-
-
0029881854
-
Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients
-
Association Francaise de Chirurgie
-
Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996;77:1254-62.
-
(1996)
Cancer
, vol.77
, pp. 1254-1262
-
-
Nordlinger, B.1
Guiguet, M.2
Vaillant, J.C.3
Balladur, P.4
Boudjema, K.5
Bachellier, P.6
-
3
-
-
0033504042
-
Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases
-
discussion 318-21
-
Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:309-18; discussion 318-21.
-
(1999)
Ann Surg
, vol.230
, pp. 309-318
-
-
Fong, Y.1
Fortner, J.2
Sun, R.L.3
Brennan, M.F.4
Blumgart, L.H.5
-
4
-
-
0026762968
-
Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: A randomized trial
-
Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 1992;10:904-11.
-
(1992)
J Clin Oncol
, vol.10
, pp. 904-911
-
-
-
5
-
-
0033005770
-
A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy
-
V301 Study Group
-
Cunningham D, Glimelius B. A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group. Semin Oncol 1999;26(1 Suppl 5):6-12.
-
(1999)
Semin Oncol
, vol.26
, Issue.1 SUPPL. 5
, pp. 6-12
-
-
Cunningham, D.1
Glimelius, B.2
-
6
-
-
0006944748
-
Number of cancer drugs in development rises in USA
-
McCarthy M. Number of cancer drugs in development rises in USA. Lancet Oncology 2001;2:256.
-
(2001)
Lancet Oncology
, vol.2
, pp. 256
-
-
McCarthy, M.1
-
7
-
-
0028219974
-
Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer
-
Advanced Colorectal Cancer Meta-Analysis Project. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994;12:960-9.
-
(1994)
J Clin Oncol
, vol.12
, pp. 960-969
-
-
-
8
-
-
0026721532
-
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate
-
Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
-
(1992)
J Clin Oncol
, vol.10
, pp. 896-903
-
-
-
9
-
-
0344109583
-
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer
-
Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16:301-8.
-
(1998)
J Clin Oncol
, vol.16
, pp. 301-308
-
-
-
10
-
-
0345596364
-
Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors
-
Meta-analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 1998;16:3537-41.
-
(1998)
J Clin Oncol
, vol.16
, pp. 3537-3541
-
-
-
11
-
-
0003241639
-
Mini-meta-analysis of toxicity of full dose Mayo regimen (FUFA) from two randomized controlled trials (RCTs): A concern about dose
-
Vincent M, Whiston F, Tomiak A. Mini-meta-analysis of toxicity of full dose Mayo regimen (FUFA) from two randomized controlled trials (RCTs): a concern about dose. Proc Am Soc Clin Oncol 1999;18:A930.
-
(1999)
Proc Am Soc Clin Oncol
, vol.18
-
-
Vincent, M.1
Whiston, F.2
Tomiak, A.3
-
12
-
-
0036499136
-
Phase II trial of chronomodulated infusion of high-dose fluorouracil and 1-folinic acid in previously untreated patients with metastatic colorectal cancer
-
Cure H, Chevalier V, Adenis A, Tubiana-Mathieu N, Niezgodzki G, Kwiatkowski F, et al. Phase II trial of chronomodulated infusion of high-dose fluorouracil and 1-folinic acid in previously untreated patients with metastatic colorectal cancer. J Clin Oncol 2002;20:1175-81.
-
(2002)
J Clin Oncol
, vol.20
, pp. 1175-1181
-
-
Cure, H.1
Chevalier, V.2
Adenis, A.3
Tubiana-Mathieu, N.4
Niezgodzki, G.5
Kwiatkowski, F.6
-
13
-
-
0023553750
-
Diurnal variation in the therapeutic efficacy of 5-fluorouracil against murine colon cancer
-
Peters GJ, Van Dijk J, Nadal JC, Van Groeningen CJ, Lankelma J, Pinedo HM. Diurnal variation in the therapeutic efficacy of 5-fluorouracil against murine colon cancer. In Vivo 1987;1:113-7.
-
(1987)
In Vivo
, vol.1
, pp. 113-117
-
-
Peters, G.J.1
Van Dijk, J.2
Nadal, J.C.3
Van Groeningen, C.J.4
Lankelma, J.5
Pinedo, H.M.6
-
14
-
-
5544237608
-
Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer
-
'Tomudex' Colorectal Cancer Study Group
-
Cunningham D, Zalcberg JR, Rath U, Oliver I, van Cutsem E, Svensson C, et al. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. 'Tomudex' Colorectal Cancer Study Group. Ann Oncol 1996;7:961-5.
-
(1996)
Ann Oncol
, vol.7
, pp. 961-965
-
-
Cunningham, D.1
Zalcberg, J.R.2
Rath, U.3
Oliver, I.4
Van Cutsem, E.5
Svensson, C.6
-
15
-
-
0031671255
-
Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer
-
Tomudex Colorectal Cancer Study Group
-
Cocconi G, Cunningham D, Van Cutsem E, Francois E, Gustavsson B, van Hazel G, et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer., Tomudex Colorectal Cancer Study Group. J Clin Oncol 1998;16:2943-52.
-
(1998)
J Clin Oncol
, vol.16
, pp. 2943-2952
-
-
Cocconi, G.1
Cunningham, D.2
Van Cutsem, E.3
Francois, E.4
Gustavsson, B.5
Van Hazel, G.6
-
16
-
-
0000269364
-
Raltitrexed (Tomudex) versus 5-fluorouracil and leucovorin (5-FU + LV) in patients with advanced colorectal cancer (ACC): Results of a randomized, multicenter, North American trial
-
Pazdur R, Vincent M. Raltitrexed (Tomudex) versus 5-fluorouracil and leucovorin (5-FU + LV) in patients with advanced colorectal cancer (ACC): results of a randomized, multicenter, North American trial. Proc Am Soc Clin Oncol 1997;16:A801.
-
(1997)
Proc Am Soc Clin Oncol
, vol.16
-
-
Pazdur, R.1
Vincent, M.2
-
17
-
-
0037018765
-
Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: A multicentre randomised trial
-
Maughan TS, James RD, Kerr DJ, Ledermann JA, McArdle C, Seymour MT, et al. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet 2002;359 (9317)1555-63.
-
(2002)
Lancet
, vol.359
, Issue.9317
, pp. 1555-1563
-
-
Maughan, T.S.1
James, R.D.2
Kerr, D.J.3
Ledermann, J.A.4
McArdle, C.5
Seymour, M.T.6
-
18
-
-
0036235187
-
Raltitrexed: Current clinical status and future directions
-
Van Cutsem E, Cunningham D, Maroun J, Cervantes A, Glimelius B. Raltitrexed: current clinical status and future directions. Ann Oncol 2002;13:513-22.
-
(2002)
Ann Oncol
, vol.13
, pp. 513-522
-
-
Van Cutsem, E.1
Cunningham, D.2
Maroun, J.3
Cervantes, A.4
Glimelius, B.5
-
19
-
-
0036186018
-
Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer, a review of phase II/III trials
-
Cunningham D, Zalcberg J, Maroun J, James R, Clarke S, Maughan TS, et al. Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer, a review of phase II/III trials. Eur J Cancer 2002;38:478-86.
-
(2002)
Eur J Cancer
, vol.38
, pp. 478-486
-
-
Cunningham, D.1
Zalcberg, J.2
Maroun, J.3
James, R.4
Clarke, S.5
Maughan, T.S.6
-
20
-
-
0009400189
-
Folate depletion is associated with haematological toxicity in patients (pts) treated with raltitrexed (Tomudex) for colorectal cancer
-
Keller OR, Vincent M, Maroun J, Fields A, Wasil T, Moore M, et al. Folate depletion is associated with haematological toxicity in patients (pts) treated with raltitrexed (Tomudex) for colorectal cancer. Proc Am Soc Clin Oncol 2001;20:141a.
-
(2001)
Proc Am Soc Clin Oncol
, vol.20
-
-
Keller, O.R.1
Vincent, M.2
Maroun, J.3
Fields, A.4
Wasil, T.5
Moore, M.6
-
21
-
-
0035016457
-
Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer
-
Volk J, Reinke F, van Kuilenburg AB, van Gennip AH, Schlichting C, Ganser A, et al. Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer. Ann Oncol 2001;12:569-71.
-
(2001)
Ann Oncol
, vol.12
, pp. 569-571
-
-
Volk, J.1
Reinke, F.2
Van Kuilenburg, A.B.3
Van Gennip, A.H.4
Schlichting, C.5
Ganser, A.6
-
22
-
-
0027194943
-
Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer
-
CPT-11 Gastrointestinal Cancer Study Group
-
Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 1993;11:909-13.
-
(1993)
J Clin Oncol
, vol.11
, pp. 909-913
-
-
Shimada, Y.1
Yoshino, M.2
Wakui, A.3
Nakao, I.4
Futatsuki, K.5
Sakata, Y.6
-
23
-
-
0029919598
-
Irinotecan is an active agent in untreated patients with metastatic colorectal cancer
-
Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chou TC, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996;14:709-15.
-
(1996)
J Clin Oncol
, vol.14
, pp. 709-715
-
-
Conti, J.A.1
Kemeny, N.E.2
Saltz, L.B.3
Huang, Y.4
Tong, W.P.5
Chou, T.C.6
-
24
-
-
0030818926
-
Phase II trial of irinotecan in patients with metastatic colorectal carcinoma
-
Pitot HC, Wender DB, O'Connell MJ, Schroeder G, Goldberg RM, Rubin J, et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997;15:2910-9.
-
(1997)
J Clin Oncol
, vol.15
, pp. 2910-2919
-
-
Pitot, H.C.1
Wender, D.B.2
O'Connell, M.J.3
Schroeder, G.4
Goldberg, R.M.5
Rubin, J.6
-
25
-
-
0031014627
-
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy
-
Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997;15:251-60.
-
(1997)
J Clin Oncol
, vol.15
, pp. 251-260
-
-
Rougier, P.1
Bugat, R.2
Douillard, J.Y.3
Culine, S.4
Suc, E.5
Brunet, P.6
-
26
-
-
0033558004
-
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma
-
Rothenberg ML, Cox JV, DeVore RF, Hainsworth JD, Pazdur R, Rivkin SE, et al. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 1999;85:786-95.
-
(1999)
Cancer
, vol.85
, pp. 786-795
-
-
Rothenberg, M.L.1
Cox, J.V.2
DeVore, R.F.3
Hainsworth, J.D.4
Pazdur, R.5
Rivkin, S.E.6
-
27
-
-
0032585232
-
Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
-
Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352 (9138)1413-8.
-
(1998)
Lancet
, vol.352
, Issue.9138
, pp. 1413-1418
-
-
Cunningham, D.1
Pyrhonen, S.2
James, R.D.3
Punt, C.J.4
Hickish, T.F.5
Heikkila, R.6
-
28
-
-
0034727063
-
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer
-
Irinotecan Study Group
-
Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-14.
-
(2000)
N Engl J Med
, vol.343
, pp. 905-914
-
-
Saltz, L.B.1
Cox, J.V.2
Blanke, C.3
Rosen, L.S.4
Fehrenbacher, L.5
Moore, M.J.6
-
29
-
-
0034712536
-
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
-
Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355 (9209)1041-7.
-
(2000)
Lancet
, vol.355
, Issue.9209
, pp. 1041-1047
-
-
Douillard, J.Y.1
Cunningham, D.2
Roth, A.D.3
Navarro, M.4
James, R.D.5
Karasek, P.6
-
30
-
-
0036137897
-
Impact of body-size measures on irinotecan clearance: Alternative dosing recommendations
-
Mathijssen RH, Verweij J, de Jonge MJ, Nooter K, Stoter G, Sparreboom A. Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. J Clin Oncol 2002;20:81-7.
-
(2002)
J Clin Oncol
, vol.20
, pp. 81-87
-
-
Mathijssen, R.H.1
Verweij, J.2
De Jonge, M.J.3
Nooter, K.4
Stoter, G.5
Sparreboom, A.6
-
31
-
-
0028022585
-
Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea
-
Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994;54:3723-5.
-
(1994)
Cancer Res
, vol.54
, pp. 3723-3725
-
-
Gupta, E.1
Lestingi, T.M.2
Mick, R.3
Ramirez, J.4
Vokes, E.E.5
Ratain, M.J.6
-
32
-
-
0035849938
-
Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer
-
author reply 146
-
Sargent DJ, Niedzwiecki D, O'Connell MJ, Schilsky RL. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 2001;345:144-5; author reply 146.
-
(2001)
N Engl J Med
, vol.345
, pp. 144-145
-
-
Sargent, D.J.1
Niedzwiecki, D.2
O'Connell, M.J.3
Schilsky, R.L.4
-
33
-
-
0035850303
-
Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer
-
Ledermann JA, Leonard P, Seymour M. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 2001;345:145-6.
-
(2001)
N Engl J Med
, vol.345
, pp. 145-146
-
-
Ledermann, J.A.1
Leonard, P.2
Seymour, M.3
-
34
-
-
0035884212
-
Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel
-
Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001;19:3801-7.
-
(2001)
J Clin Oncol
, vol.19
, pp. 3801-3807
-
-
Rothenberg, M.L.1
Meropol, N.J.2
Poplin, E.A.3
Van Cutsem, E.4
Wadler, S.5
-
35
-
-
0034006524
-
Clinical pharmacokinetics of oxaliplatin: A critical review
-
Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 2000;6:1205-18.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 1205-1218
-
-
Graham, M.A.1
Lockwood, G.F.2
Greenslade, D.3
Brienza, S.4
Bayssas, M.5
Gamelin, E.6
-
36
-
-
0004700371
-
Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study
-
Diaz-Rubio E, Sastre J, Zaniboni A, Labianca R, Cortes-Funes H, de Braud F, et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 1998;9:105-8.
-
(1998)
Ann Oncol
, vol.9
, pp. 105-108
-
-
Diaz-Rubio, E.1
Sastre, J.2
Zaniboni, A.3
Labianca, R.4
Cortes-Funes, H.5
De Braud, F.6
-
37
-
-
0344783805
-
Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients
-
Digestive Group of French Federation of Cancer Centers
-
Becouarn Y, Ychou M, Ducreux M, Borel C, Bertheault-Cvitkovic F, Seitz JF, et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol 1998;16:2739-44.
-
(1998)
J Clin Oncol
, vol.16
, pp. 2739-2744
-
-
Becouarn, Y.1
Ychou, M.2
Ducreux, M.3
Borel, C.4
Bertheault-Cvitkovic, F.5
Seitz, J.F.6
-
38
-
-
0039276846
-
A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma
-
International Organization for Cancer Chronotherapy
-
Levi F, Zidani R, Brienza S, Dogliotti L, Perpoint B, Rotarski M, et al. A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy. Cancer 1999;85:2532-40.
-
(1999)
Cancer
, vol.85
, pp. 2532-2540
-
-
Levi, F.1
Zidani, R.2
Brienza, S.3
Dogliotti, L.4
Perpoint, B.5
Rotarski, M.6
-
39
-
-
0026512446
-
A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer
-
Levi F, Misset JL, Brienza S, Adam R, Metzger G, Itzakhi M, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 1992;69:893-900.
-
(1992)
Cancer
, vol.69
, pp. 893-900
-
-
Levi, F.1
Misset, J.L.2
Brienza, S.3
Adam, R.4
Metzger, G.5
Itzakhi, M.6
-
40
-
-
10344253782
-
Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer
-
Bertheault-Cvitkovic F, Jami A, Ithzaki M, Brummer PD, Brienza S, Adam R, et al. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 1996;14:2950-8.
-
(1996)
J Clin Oncol
, vol.14
, pp. 2950-2958
-
-
Bertheault-Cvitkovic, F.1
Jami, A.2
Ithzaki, M.3
Brummer, P.D.4
Brienza, S.5
Adam, R.6
-
41
-
-
0030888321
-
Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer
-
de Gramont A, Vignoud J, Tournigand C, Louvet C, Andre T, Varette C, et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997;33:214-9.
-
(1997)
Eur J Cancer
, vol.33
, pp. 214-219
-
-
De Gramont, A.1
Vignoud, J.2
Tournigand, C.3
Louvet, C.4
Andre, T.5
Varette, C.6
-
42
-
-
0032730143
-
Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen
-
Andre T, Bensmaine MA, Louvet C, Francois E, Lucas V, Desseigne F, et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999;17:3560-8.
-
(1999)
J Clin Oncol
, vol.17
, pp. 3560-3568
-
-
Andre, T.1
Bensmaine, M.A.2
Louvet, C.3
Francois, E.4
Lucas, V.5
Desseigne, F.6
-
43
-
-
0033636033
-
Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer
-
Oncology Multidisciplinary Research Group (GERCOR)
-
Maindrault-Goebel F, de Gramont A, Louvet C, Andre T, Carola E, Gilles V, et al. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR), Ann Oncol 2000;11:1477-83.
-
(2000)
Ann Oncol
, vol.11
, pp. 1477-1483
-
-
Maindrault-Goebel, F.1
De Gramont, A.2
Louvet, C.3
Andre, T.4
Carola, E.5
Gilles, V.6
-
44
-
-
0033989203
-
Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer
-
Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-47.
-
(2000)
J Clin Oncol
, vol.18
, pp. 136-147
-
-
Giacchetti, S.1
Perpoint, B.2
Zidani, R.3
Le Bail, N.4
Faggiuolo, R.5
Focan, C.6
-
45
-
-
0033874892
-
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
-
de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47.
-
(2000)
J Clin Oncol
, vol.18
, pp. 2938-2947
-
-
De Gramont, A.1
Figer, A.2
Seymour, M.3
Homerin, M.4
Hmissi, A.5
Cassidy, J.6
-
46
-
-
0029794696
-
Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy
-
discussion 520-2
-
Bismuth H, Adam R, Levi F, Farabos C, Waechter F, Castaing D, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996;224:509-20; discussion 520-2.
-
(1996)
Ann Surg
, vol.224
, pp. 509-20
-
-
Bismuth, H.1
Adam, R.2
Levi, F.3
Farabos, C.4
Waechter, F.5
Castaing, D.6
-
47
-
-
0032791959
-
Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery
-
Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999;10:663-9.
-
(1999)
Ann Oncol
, vol.10
, pp. 663-669
-
-
Giacchetti, S.1
Itzhaki, M.2
Gruia, G.3
Adam, R.4
Zidani, R.5
Kunstlinger, F.6
-
48
-
-
0012042189
-
Oxaliplatin (OXAL), 5-fluorouracil (5FU), and leucovorin (CF) for patients (pts) with liver only metastases (mets) from colorectal cancer (CRC): A North Central Cancer Treatment Group (NCCTG) phase II study
-
Alberts SR, Horvath W, Donohue JH, Sternfeld W, Goldberg RM, Mahoney MR, et al. Oxaliplatin (OXAL), 5-fluorouracil (5FU), and leucovorin (CF) for patients (pts) with liver only metastases (mets) from colorectal cancer (CRC): a North Central Cancer Treatment Group (NCCTG) phase II study. Proc Am Soc Clin Oncol 2001;20:129a.
-
(2001)
Proc Am Soc Clin Oncol
, vol.20
-
-
Alberts, S.R.1
Horvath, W.2
Donohue, J.H.3
Sternfeld, W.4
Goldberg, R.M.5
Mahoney, M.R.6
-
49
-
-
0012797224
-
Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines
-
Machover D, Diaz-Rubio E, de Gramont A, Schilf A, Gastiaburu JJ, Brienza S, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996;7:95-8.
-
(1996)
Ann Oncol
, vol.7
, pp. 95-98
-
-
Machover, D.1
Diaz-Rubio, E.2
De Gramont, A.3
Schilf, A.4
Gastiaburu, J.J.5
Brienza, S.6
-
50
-
-
0036534144
-
Acute oxaliplatin-induced peripheral nerve hyperexcitability
-
Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 2002;20:1767-74.
-
(2002)
J Clin Oncol
, vol.20
, pp. 1767-1774
-
-
Wilson, R.H.1
Lehky, T.2
Thomas, R.R.3
Quinn, M.G.4
Floeter, M.K.5
Grem, J.L.6
-
51
-
-
0036018894
-
Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer
-
Lersch C, Schmelz R, Eckel F, Erdmann J, Mayr M, Schulte-Frohlinde E, et al. Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer. Clin Colorectal Cancer 2002;2:54-8.
-
(2002)
Clin Colorectal Cancer
, vol.2
, pp. 54-58
-
-
Lersch, C.1
Schmelz, R.2
Eckel, F.3
Erdmann, J.4
Mayr, M.5
Schulte-Frohlinde, E.6
-
52
-
-
0037126944
-
Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study
-
Eckel F, Schmelz R, Adelsberger H, Erdmann J, Quasthoff S, Lersch C. [Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study]. Dtsch Med Wochenschr 2002;127:78-82.
-
(2002)
Dtsch Med Wochenschr
, vol.127
, pp. 78-82
-
-
Eckel, F.1
Schmelz, R.2
Adelsberger, H.3
Erdmann, J.4
Quasthoff, S.5
Lersch, C.6
-
53
-
-
2042531025
-
Prevention of oxaliplatin induced periferal sensory neuropathy by carbamazepine in patients with advanced colorectal cancer
-
Eckel F, Schmelz R, Erdmann J, Nader M, Adelsberger H, Grosskreutz J, et al. Prevention of oxaliplatin induced periferal sensory neuropathy by carbamazepine in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 2001;20:146a.
-
(2001)
Proc Am Soc Clin Oncol
, vol.20
-
-
Eckel, F.1
Schmelz, R.2
Erdmann, J.3
Nader, M.4
Adelsberger, H.5
Grosskreutz, J.6
-
54
-
-
0037010088
-
Clinical aspects and molecular basis of oxaliplatin neurotoxicity: Current management and development of preventive measures
-
Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 2002;29 (5 Suppl 15) 21-33.
-
(2002)
Semin Oncol
, vol.29
, Issue.5 SUPPL. 15
, pp. 21-33
-
-
Gamelin, E.1
Gamelin, L.2
Bossi, L.3
Quasthoff, S.4
-
55
-
-
0036534144
-
Acute oxaliplatin-induced peripheral nerve hyperexcitability
-
Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 2002;20:1767-74.
-
(2002)
J Clin Oncol
, vol.20
, pp. 1767-1774
-
-
Wilson, R.H.1
Lehky, T.2
Thomas, R.R.3
Quinn, M.G.4
Floeter, M.K.5
Grem, J.L.6
-
57
-
-
0031017851
-
Patient preferences for oral versus intravenous palliative chemotherapy
-
Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-5.
-
(1997)
J Clin Oncol
, vol.15
, pp. 110-115
-
-
Liu, G.1
Franssen, E.2
Fitch, M.I.3
Warner, E.4
-
58
-
-
0019378585
-
Dose-response effect of adjuvant chemotherapy in breast cancer
-
Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981;304:10-5.
-
(1981)
N Engl J Med
, vol.304
, pp. 10-15
-
-
Bonadonna, G.1
Valagussa, P.2
-
60
-
-
0037087668
-
Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer
-
Schilsky RL, Levin J, West WH, Wong A, Colwell B, Thirlwell MP, et al. Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. J Clin Oncol 2002;20:1519-26.
-
(2002)
J Clin Oncol
, vol.20
, pp. 1519-1526
-
-
Schilsky, R.L.1
Levin, J.2
West, W.H.3
Wong, A.4
Colwell, B.5
Thirlwell, M.P.6
-
61
-
-
0003300519
-
International phase III study of oral eniluracil (EU) plus 5-fluorouracil (5-FU) versus intravenous (iv) 5-FU plus leucovorin (LV) in the treatment of advanced colorectal cancer (ACC)
-
Van Cutsem E, Sorensen J, Cassidy J, Daniel F, Harper P, Bailey N, et al. International phase III study of oral eniluracil (EU) plus 5-fluorouracil (5-FU) versus intravenous (iv) 5-FU plus leucovorin (LV) in the treatment of advanced colorectal cancer (ACC). Proc Am Soc Clin Oncol 2001;20:131a.
-
(2001)
Proc Am Soc Clin Oncol
, vol.20
-
-
Van Cutsem, E.1
Sorensen, J.2
Cassidy, J.3
Daniel, F.4
Harper, P.5
Bailey, N.6
-
62
-
-
0034016415
-
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients
-
Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000;45:291-7.
-
(2000)
Cancer Chemother Pharmacol
, vol.45
, pp. 291-297
-
-
Schuller, J.1
Cassidy, J.2
Dumont, E.3
Roos, B.4
Durston, S.5
Banken, L.6
-
63
-
-
0034016343
-
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study
-
Van Cutsem E, Findlay M, Osterwalder B, Kocha W, Dalley D, Pazdur R, et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 2000;18:1337-45.
-
(2000)
J Clin Oncol
, vol.18
, pp. 1337-1345
-
-
Van Cutsem, E.1
Findlay, M.2
Osterwalder, B.3
Kocha, W.4
Dalley, D.5
Pazdur, R.6
-
64
-
-
0035503151
-
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study
-
Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:4097-106.
-
(2001)
J Clin Oncol
, vol.19
, pp. 4097-4106
-
-
Van Cutsem, E.1
Twelves, C.2
Cassidy, J.3
Allman, D.4
Bajetta, E.5
Boyer, M.6
-
65
-
-
0035871538
-
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study
-
Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19:2282-92.
-
(2001)
J Clin Oncol
, vol.19
, pp. 2282-2292
-
-
Hoff, P.M.1
Ansari, R.2
Batist, G.3
Cox, J.4
Kocha, W.5
Kuperminc, M.6
-
66
-
-
0036731818
-
Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer
-
Douillard JY, Hoff PM, Skillings JR, Eisenberg P, Davidson N, Harper P, et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002;20:3605-16.
-
(2002)
J Clin Oncol
, vol.20
, pp. 3605-3616
-
-
Douillard, J.Y.1
Hoff, P.M.2
Skillings, J.R.3
Eisenberg, P.4
Davidson, N.5
Harper, P.6
-
67
-
-
0036727089
-
Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer
-
Carmichael J, Popiela T, Radstone D, Falk S, Borner M, Oza A, et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002;20:3617-27.
-
(2002)
J Clin Oncol
, vol.20
, pp. 3617-3627
-
-
Carmichael, J.1
Popiela, T.2
Radstone, D.3
Falk, S.4
Borner, M.5
Oza, A.6
-
68
-
-
0036159485
-
Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: A randomised crossover trial in advanced colorectal cancer
-
Borner MM, Schoffski P, de Wit R, Caponigro F, Comella G, Sulkes A, et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002;38:349-58.
-
(2002)
Eur J Cancer
, vol.38
, pp. 349-358
-
-
Borner, M.M.1
Schoffski, P.2
De Wit, R.3
Caponigro, F.4
Comella, G.5
Sulkes, A.6
-
69
-
-
0034779291
-
The EGFR as a target for anticancer therapy: Focus on cetuximab
-
Baselga J. The EGFR as a target for anticancer therapy: focus on cetuximab. Eur J Cancer 2001;37 Suppl 4:S16-22.
-
(2001)
Eur J Cancer
, vol.37
, Issue.4 SUPPL.
-
-
Baselga, J.1
-
70
-
-
0002823211
-
Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR)
-
Saltz L, Rubin M, Hochster H, Tchekmeydian NS, Waksal H, Needle M, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001;20:3a.
-
(2001)
Proc Am Soc Clin Oncol
, vol.20
-
-
Saltz, L.1
Rubin, M.2
Hochster, H.3
Tchekmeydian, N.S.4
Waksal, H.5
Needle, M.6
-
71
-
-
0001407135
-
Single agent IMC-C225 (Erbitux) has activity in CPT-11-refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR)
-
Saltz L, Meropol NJ, Loehrer PJ, Waksal H, Needle M, Mayer RJ. Single agent IMC-C225 (Erbitux) has activity in CPT-11-refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2002;21:A504.
-
(2002)
Proc Am Soc Clin Oncol
, vol.21
-
-
Saltz, L.1
Meropol, N.J.2
Loehrer, P.J.3
Waksal, H.4
Needle, M.5
Mayer, R.J.6
-
72
-
-
0001407137
-
Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR)
-
Rosenberg AH, Loehrer PJ, Needle M, Waksal H, Hollywood E, Ramos L, et al. Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2002;21:A536.
-
(2002)
Proc Am Soc Clin Oncol
, vol.21
-
-
Rosenberg, A.H.1
Loehrer, P.J.2
Needle, M.3
Waksal, H.4
Hollywood, E.5
Ramos, L.6
-
73
-
-
0037208589
-
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
-
Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-5.
-
(2003)
J Clin Oncol
, vol.21
, pp. 60-65
-
-
Kabbinavar, F.1
Hurwitz, H.I.2
Fehrenbacher, L.3
Meropol, N.J.4
Novotny, W.F.5
Lieberman, G.6
-
74
-
-
1642640254
-
Bi-weekly irinotecan (CPT-11), oxaliplatin (LOHP), leucovorin (LV) and 5-fluorouracil (5-FU) 48 hours continuous infusion in advanced colorectal cancer (ACRC)
-
Masi G, Allegrini G, Danesi R, Di Paulo A, Cupini S, Marcucci L, et al. Bi-weekly irinotecan (CPT-11), oxaliplatin (LOHP), leucovorin (LV) and 5-fluorouracil (5-FU) 48 hours continuous infusion in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2002;21:A673.
-
(2002)
Proc Am Soc Clin Oncol
, vol.21
-
-
Masi, G.1
Allegrini, G.2
Danesi, R.3
Di Paulo, A.4
Cupini, S.5
Marcucci, L.6
-
75
-
-
0345455369
-
Oxaliplatin (L-OHP) combined with irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5-FU) (FOLFOXIRI) compared with CPT-11, LV and 5-FU (FOLFIRI) as first-line treatment for metastatic colorectal cancer: Preliminary safety and efficacy results of multicenter randomized trial
-
Souglakos J, Athanasiadis A, Ginopoulos P, Giannakakis T, Syrigos K, Kourousis C, et al. Oxaliplatin (L-OHP) combined with irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5-FU) (FOLFOXIRI) compared with CPT-11, LV and 5-FU (FOLFIRI) as first-line treatment for metastatic colorectal cancer: preliminary safety and efficacy results of multicenter randomized trial. Proc Am Soc Clin Oncol 2002;21:A608.
-
(2002)
Proc Am Soc Clin Oncol
, vol.21
-
-
Souglakos, J.1
Athanasiadis, A.2
Ginopoulos, P.3
Giannakakis, T.4
Syrigos, K.5
Kourousis, C.6
-
76
-
-
0012042070
-
Oxaliplatin (OXA) combined with irinotecan (CPT-11) and 5FU/leucovorin (OCFL) in metastatic colorectal cancer (MCRC): A phase I-II study
-
Roth AD, Seium Y, Ruhstaller T, Bauer J, Soravia C, Mentha G, et al. Oxaliplatin (OXA) combined with irinotecan (CPT-11) and 5FU/leucovorin (OCFL) in metastatic colorectal cancer (MCRC): a phase I-II study. Proc Am Soc Clin Oncol 2002;21:A570.
-
(2002)
Proc Am Soc Clin Oncol
, vol.21
-
-
Roth, A.D.1
Seium, Y.2
Ruhstaller, T.3
Bauer, J.4
Soravia, C.5
Mentha, G.6
-
77
-
-
0034642607
-
Genetic prognostic markers for colorectal cancer
-
Offit K. Genetic prognostic markers for colorectal cancer. N Engl J Med 2000;342:124-5.
-
(2000)
N Engl J Med
, vol.342
, pp. 124-125
-
-
Offit, K.1
|